Mission
To identify and address specific oncology outcomes research issues and to develop recommendations to address these issues.
Background
The field of oncology outcomes research is complicated by the diversity of diseases within oncology, the rapidly changing nature of treatments, and the complexities of measuring cost, and quality of life - patient reported outcomes. As such, oncology outcomes research constitutes a unique segment of outcomes research, one that requires specific clinical and methodological knowledge for its proper conduct.
Leadership
Chair-Elect
Haitham Tuffaha, MSc, MBA, RPh, PhD, BSc
Health Technology Assessment Leader, University of Queensland, Centre for the Business and Economics of Health
Brisbane, QLD, Australia
Chair
Sang Kyu Cho, PharmD, MPH
Associate, Analysis Group
Boston, MA, United States
Working Groups
Member Engagement
Co-Chairs
Abeer Al Rabayah, MSc, MBA, BSc
Head, Center for Drug Policy & Technology Assessment, King Hussein Cancer Center
Amman, Jordan
Dem Aliaj
MSc, University of Lucerne
Kriens, LU, Switzerland
Brittany Carson, PhD, MHEcon, BSc
Medical Director, ApotheCom
New York, NY, United States
Kathryn Chung
AD Market Access, MSD
Singapore, 01, Singapore
Christopher Graham, MS, BS
Senior Director, Health Economics, RTI Health Solutions
Durham, NC, United States
Min-Hua Jen, PhD
Director, Eli Lilly
Uxbridge, LON, United Kingdom
Sorrel Wolowacz, PhD
Head, EU Health Economics, RTI Health Solutions
Manchester, United Kingdom
Questions or ideas? Please send an email to Oncologysig@ISPOR.org